


What is obesity?

Obesity is a serious chronic disease, and a major global health challenge. Novo Nordisk is committed to improving the lives of people with obesity by changing how the world sees, prevents and treats obesity.

In order to tackle obesity and the complications associated with it, we are advocating for a shift from the individual to a shared societal responsibility as we work together to build healthier environments, foster empathy and make obesity a healthcare priority.



Obesity is commonly measured using body mass index (BMI), and is classified by having a BMI of 30 kg/m² or greater.¹

The burden of obesity

Obesity-related complications include **type 2 diabetes** and **cardiovascular disease**.³

Obesity can also have an impact on a person's **mental health** and **quality of life**.^{4,5}

Annually, obesity accounts for **USD 2 trillion** (DKK 12 trillion) in global healthcare costs.⁶


Outside of healthcare, obesity is also costly in the form of lost productivity including **sick days, reduced efficiency** at work and permanent **disability**.⁷

Obesity is a multifactorial disease, but there remains an underlying societal belief that obesity is a result of lack of willpower, which can lead to people with obesity being subjected to blame and stigma in the family, at work or in society at large.^{4,5} The majority of people with obesity also believe weight management is their own responsibility and that they have to change their lifestyle.

Preventing obesity is a priority as obesity is linked to many complications – some of which may impact life expectancy and health-related quality of life.⁸ In addition, children and adolescents living with obesity are at a higher risk of developing serious health problems at a younger age and are more likely to live with obesity into adulthood.⁹

Losing excessive weight has a positive impact on health

The health benefits of losing weight and keeping it off can be substantial:



For more information on obesity and Novo Nordisk's commitment to driving change in obesity, visit:

novonordisk.com/disease-areas/obesity.html

References: **1.** World Health Organization. Obesity and Overweight Factsheet no. 311. Available at: <http://www.who.int/mediacentre/factsheets/fs311/en/>. Last accessed: December 2020. **2.** World Obesity Federation. Atlas of Childhood Obesity. Available at: http://s3-eu-west-1.amazonaws.com/wof-files/WOF_Childhood_Obesity_Atlas_Report_Oct19_V2.pdf. Last accessed: December 2020. **3.** Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. *The Lancet Diabetes & Endocrinology*. 2015; 3:114–122. **4.** Phelan S, Burgess DJ, Yeazel MW, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. *Obesity Reviews*. 2015; 16:319–326. **5.** Puhl RM and Brownell KD. Confronting and coping with weight stigma: an investigation of overweight and obese adults. *Obesity*. 2006; 14:1802–1815. **6.** Kishore M, Gadde MD, Corby KM et al. Obesity: Pathophysiology and Management. *J Am Coll Cardiol*. 2018;71:69–84; **7.** Heymsfield SB and Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. *N Engl J Med*. 2017;376:1492. **8.** Yuen M, Earle R, Kadambi N, et al. A systematic review and evaluation of current evidence reveals 195 obesity-associated disorders. Poster abstract presentation at: The Obesity Society Annual Meeting at ObesityWeek 2016; Oct. 31 - Nov. 4, 2016; New Orleans. **9.** WHO. Childhood overweight and obesity. Available at: <https://www.who.int/dietphysicalactivity/childhood/en/>. Last accessed: December 2020. **10.** Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. *Endocr Pract*. 2016 Jul;22 Suppl 3:1-203. **11.** Haase C, Lopes S, and Olsen A et al., Weight loss and risk reduction of obesity-related conditions in 0.5 million people: evidence from a UK primary care database. Abstract presented at ECO-ICO Online, 1–4 September 2020. **12.** Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. *Lancet*. 2017; 389:1399–1409. **13.** Dattilo AM and Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr*. 1992; 56:320–328. **14.** Mahil SK, McSweeney SM, Kloczko E, et al. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A Critically Appraised Topic. *Br J Dermatol*. 2019; 181:946–953. **15.** Warkentin LM, Das D, Majumdar SR, et al. The effect of weight loss on health-related quality of life: systematic review and meta-analysis of randomized trials. *Obes Rev*. 2014;15:169–182.